News >

Alectinib Beats Crizotinib in Frontline ALK+ NSCLC ALEX Trial

Jason M. Broderick @jasoncology
Published: Monday, Apr 10, 2017

Sandra Horning, MD

Sandra Horning, MD

Alectinib (Alecensa) reduced the risk of disease progression or death compared with crizotinib (Xalkori) as a frontline treatment for patients with ALK-positive non–small cell lung cancer (NSCLC), according to findings from the phase III ALEX trial.

-positive NSCLC who had progressed following treatment with platinum-based chemotherapy and crizotinib.
Nokihara H, Hida T, Kondo M, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. Presented at: 2016 ASCO Annual Meeting; June 3-7, 2016; Chicago. Abstract 9008.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication